Gokhan Batur joined Alkapharmics as Chief Executive Officer in 2024. He is a life sciences executive with more than 20 years of experience in commercial, corporate development (portfolio strategy, financing and BD) and drug development (pre-IND to pivotal clinical trials including product launches). Formerly he was the CEO at Polyphor, a late-stage publicly listed Swiss biotech focused on oncology and anti-infectives. Prior to this he assumed various management roles for 15 years at MSD (known as Merck Co. & Inc in the United States), most recently serving as Global Brand Leader, Antibiotics, responsible for leading the entire Merck antibiotics portfolio managing multiple in-line and pipeline products and sales of ~$2B. In addition to his role at Alkapharmics, Gokhan is a venture partner at XGEN Venture (Italy), board member at APIM Therapeutics (Norway) and Santero Therapeutics (Belgium).

Dr. Mullan earned his medical and Ph.D. degrees from the University of London. Dr. Mullan has previously served as CEO or CSO of both publicly traded and private drug development companies. He co-founded the Roskamp Institute, a biomedical not for profit research facility in 2003. He has over 350 peer-reviewed publications primarily in neurobiology and inflammation. He is an inventor on multiple patents related to the treatment of inflammatory disorders.

Julia Hoeng leads the Cannabinoids Science Center at Vectura Fertin Pharma, focusing on early opportunities and scientific innovation for cannabinoid-based products. With extensive expertise in external innovation strategies within the life sciences, she has developed products, technologies, and partnerships that advance business objectives. Julia pioneered Systems Toxicology Based Approaches for Risk Assessment at Philip Morris International and has held significant roles, including Global Head of Discovery Life Sciences. She has 20 years of industry experience in areas such as inhalation toxicology, drug discovery, and tobacco harm reduction.

Daniel Paris received his Masters and Ph.D degrees in biochemistry, molecular and cell biology from the University of Paris. He has more than 30 years of experience in research and development, particularly in the field of neurodegenerative disorders. He has held various academic and research positions, contributing significantly to the understanding and treatment of diseases such as Alzheimer's disease. Daniel's work focuses on developing innovative therapies and identifying potential compounds for treatment strategies. He is an inventor on multiple treatment patents for neurological and inflammatory disorders.

 Manuel Peitsch holds a B.Sc. in Life Sciences, an M.Sc. in Physical Chemistry and a Ph.D. in Biochemistry. He has 15 years of experience in senior research positions in the pharmaceutical industry (GlaxoWellcome/GSK and Novartis) and seven years in academia. Manuel has published over 380 articles and book chapters and holds several patents in biotechnology and computational biology. He has conducted pioneering work in the area of bioinformatics and molecular modeling, computational text analytics, cell biology and systems biology / toxicology. Until 2023 he was Chief Scientific Officer at PMI where he led the scientific assessment of novel tobacco and nicotine products that have the potential to reduce the risk of harm and smoking-related disease. He is a co-founder of two start-up companies and the Swiss Institute of Bioinformatics (SIB) and currently is a scientific advisor to several academic and commercial entities.